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Introduction {#sec001}
============

Methicillin-resistant *Staphylococcus aureus* (MRSA) infection is an important clinical concern in patients and is often associated with significant disease burden and metastatic infections. The relative morbidity and mortality of MRSA infections are two-fold higher than that of methicillin-susceptible *S*. *aureus* (MSSA) infections \[[@pone.0227009.ref001]\]. Vancomycin is often recommended as the antibiotic of the first choice. An appropriate vancomycin prescription requires a susceptible minimum inhibitory concentration (MIC) of ≤ 1.5 μg/ml to avoid treatment failure. The Clinical Laboratory Standards Institute (CLSI) guidelines suggest *S*. *aureus* strains with a vancomycin MIC of ≤ 2 μg/ml should be classified as susceptible; 4--8 μg/ml as intermediate and ≥ 8 μg/ml as resistant \[[@pone.0227009.ref002]\]. The European Committee on Antimicrobial Sensitivity Testing (EUCAST) guidelines, defines the vancomycin MIC breakpoint of \> 2 μg/ml for non-susceptible *S*. *aureus* strains \[[@pone.0227009.ref003]\]. In contrast to vancomycin, widely different teicoplanin susceptibility breakpoints have been defined by CLSI (≤ 8 μg/ml) and EUCAST (≤ 2 μg/ml) guidelines \[[@pone.0227009.ref002],[@pone.0227009.ref003]\]. Therefore, strains with vancomycin or teicoplanin MIC of \> 2 μg/ml reflect a higher likelihood of clinical treatment failure. \[[@pone.0227009.ref003],[@pone.0227009.ref004]\].

A higher vancomycin and teicoplanin MIC of ≥ 1.5 μg/ml has been linked to poor clinical outcomes in patients with MRSA bacteremia \[[@pone.0227009.ref005]--[@pone.0227009.ref007]\]. In recent years, heterogeneous vancomycin-intermediate *S*. *aureus* (hVISA) and vancomycin-intermediate *S*. *aureus* (VISA) have been frequently reported worldwide \[[@pone.0227009.ref008]--[@pone.0227009.ref011]\]. The hVISA phenotype contains a subpopulation of cells expressing high vancomycin MIC. These subpopulations are present at the approximate frequencies of 10^−4^ to 10^−6^. \[[@pone.0227009.ref012],[@pone.0227009.ref013]\]. Studies have suggested that hVISA infections are associated with persistent bacteremia, treatment failure, and poor outcomes \[[@pone.0227009.ref014]\]. Notably, teicoplanin resistant MRSA (\>8 μg/ml) has been documented with a gradual rise in vancomycin MIC (2 to 4 μg/ml) \[[@pone.0227009.ref015]\]. However, *van*A mediating high-level vancomycin resistance in *S*. *aureus* is rare.

CLSI-recommended MIC testing methods \[[@pone.0227009.ref016]\], of broth microdilution (BMD) and agar dilution (AD) method are reported to have sub-optimal sensitivity in detecting hVISA and heterogeneous resistance to teicoplanin \[[@pone.0227009.ref015]\]. These subpopulations grow slowly with characteristic features of pin-pointed colonies, loss of pigmentation, and change in haemolytic pattern \[[@pone.0227009.ref017]\]. However, an optimal method is not available for the reliable detection of hVISA in clinical isolates due to i) the multiple and complex molecular bases of hVISA, ii) there being no single specific molecular marker for detection because of the possibility of sequential accumulation of chromosomal mutations and iii) the unpredictable phenotypic expression of hVISA, which is significantly influenced by several technical parameters including variable time frame and inoculum sizes \[[@pone.0227009.ref008]\].

Many reports have linked cell wall thickening, reduced autolysis, and decreased surface anionic charges with hVISA/VISA subpopulations \[[@pone.0227009.ref018]\]. Excess of D-Ala-D-Ala targets in the cell wall serves as a molecular sink which impedes the penetration of vancomycin towards pentapeptide targets \[[@pone.0227009.ref019]\]. Further, the hVISA/VISA phenotypes are associated with mutations in the *vra*SR (vancomycin resistance associated sensor/regulator), *gra*SR (glycopeptide resistance--associated sensor/regulator), and *wal*KR (sensor protein kinase/regulator) genes of two component systems (TCS) \[[@pone.0227009.ref017]\]. Studies have also reported the upregulation of *vra*SR in hVISA/VISA, which is under the regulation of *yvqF*, a cell wall stimulon that responds to cell wall active antibiotics \[[@pone.0227009.ref020]\]. An amino acid substitution (H481Y/ H481N) in *rpo*B, results in an elevated surface membrane charge. This is attributed to cause cross-resistance between vancomycin and daptomycin, which are functionally cationic molecules \[[@pone.0227009.ref017]\].

The development of resistance to teicoplanin on therapy is occasionally described in MRSA cases \[[@pone.0227009.ref009],[@pone.0227009.ref021]\]. MRSA strains resistant to teicoplanin but susceptible to vancomycin are also reported in the literature \[[@pone.0227009.ref022]\]. Few studies have tracked the genetic basis of teicoplanin resistance in MRSA \[[@pone.0227009.ref023]--[@pone.0227009.ref026]\]. The presence of a teicoplanin resistance operon (*tca*RAB) or the inactivation of *tca*A are reported to be associated with teicoplanin resistance in *S*. *aureus* \[[@pone.0227009.ref025]--[@pone.0227009.ref027]\].

For treating MRSA infections, vancomycin is the antibiotic of the first choice, but teicoplanin is considered in cases of osteomyelitis and septic arthritis. Teicoplanin is not approved for use in the United States, while commonly used in Europe. Observational studies and case reports documented that, in *S*. *aureus*, teicoplanin resistance emerges earlier than vancomycin resistance. \[[@pone.0227009.ref028], [@pone.0227009.ref029], [@pone.0227009.ref015]\]. Vancomycin susceptible revertant of VISA/VRSA can able to maintain the intermediate level of teicoplanin resistance. Acquisition of teicoplanin resistance is frequently accompanied by a small increase in vancomycin resistance \[[@pone.0227009.ref030]\]. An *in-vitro* study has demonstrated that overexpression of PBP2 in *S*. *aureus* increases vancomycin MIC from 1 to 2 μg/ml and teicoplanin MIC from 2 to 8 μg/ml \[[@pone.0227009.ref031]\]. Thus, extrapolating vancomycin MICs for teicoplanin therapy may result in therapeutic failure. In fact, patients who have failed teicoplanin therapy have been successfully treated with vancomycin \[[@pone.0227009.ref029]\].

The present study aims are i) to describe the phenotypic characterisation of teicoplanin resistant MRSA (TR-MRSA) and hVISA isolated from bloodstream infections, ii) to identify amino acid substitutions in the candidate genes that are associated with the development of these phenotypes, and iii) to determine the genotypes of TR-MRSA and hVISA.

Materials and methods {#sec002}
=====================

Bacterial strains {#sec003}
-----------------

A total of 482 MRSA isolates recovered from blood culture samples during 2013--2017, were included in this study. All *S*. *aureus* strains were identified using standard microbiological methods using gram staining, catalase and coagulase tests \[[@pone.0227009.ref032]\]. All isolates were stored in tryptic soy broth containing 80% (v/v) glycerol at -70⁰C. The study was conducted at a 2,600 bedded tertiary care hospital, Christian Medical College, Vellore.

Antimicrobial susceptibility testing {#sec004}
------------------------------------

Methicillin resistance in *S*. *aureus* strains was detected using cefoxitin (30 μg) disc diffusion method as per the CLSI recommendation \[[@pone.0227009.ref002]\]. For all MRSA isolates, the MIC of vancomycin and teicoplanin was determined using the broth microdilution method (BMD) \[[@pone.0227009.ref016]\]. *S*. *aureus* ATCC 29213 was used as an internal quality control strain. Isolates with a teicoplanin MIC of \> 2 μg/ml are referred to as TR-MRSA.

Screening of MRSA isolates for hVISA {#sec005}
------------------------------------

The detailed flowchart representing the screening, confirmation, and molecular characterisation of hVISA and TR-MRSA is shown in [Fig 1](#pone.0227009.g001){ref-type="fig"}.

![Algorithm used to test MRSA (n = 482) isolates for the presence of heterogeneous vancomycin-intermediate *S*. *aureus* (hVISA) subpopulation and heterogenous resistance to teicoplanin.\
hVISA---heterogenous vancomycin-intermediate *S*. *aureus*; GRD---Glycopeptide resistance detection; PAP-AUC---Population analysis profile-Area under Curve method; SCC*mec*---Staphylococcal cassette chromosome *mec; agr---*accessory gene regulator; *spa*--Staphylococcal protein A; MLST--Multilocus sequence typing; PBP- penicillin-binding protein.](pone.0227009.g001){#pone.0227009.g001}

### Vancomycin screen agar {#sec006}

All MRSA isolates were preliminarily screened for the presence of hVISA subpopulation using brain heart infusion agar (BHIA) containing 3 μg/ml (BHIV3) and 4 μg/ml (BHIV4) of vancomycin \[[@pone.0227009.ref029]\]. The colony forming unit (CFU) per droplet were counted as suggested by Khatib *et al*. \[[@pone.0227009.ref033]\].

### Macro E-test (MET) {#sec007}

MET was performed as described by Satola *et al*. \[[@pone.0227009.ref034]\]. Bacterial suspension of colonies from an overnight culture on blood agar was prepared in Mueller-Hinton broth (MHB). Turbidity was adjusted to the McFarland standard of 2.0. A volume of 200μl of the inoculum was plated onto BHIA and swabbed evenly on the agar surface. Vancomycin (0.016 to 256 μg/ml) and teicoplanin (0.016 to 256 μg/ml) E-test strips (bioMérieux, [Marcy-l\'Étoile, France](https://www.google.com/search?newwindow=1&q=Marcy-l'%C3%89toile&stick=H4sIAAAAAAAAAOPgE-LUz9U3SLMoK6pQ4gIxjQtzzM2NtbSyk63084vSE_MyqxJLMvPzUDhWGamJKYWliUUlqUXFAIlpjw9FAAAA&sa=X&ved=2ahUKEwjwgNLqta_fAhVDcCsKHfAlCqEQmxMoATATegQIBxAL)) were placed onto the inoculated BHIA and incubated at 37⁰C for 48 hrs. The test isolate was considered positive for hVISA, if the MIC for teicoplanin alone was ≥ 12 μg/ml or if the MIC for teicoplanin and vancomycin was ≥8 μg/ml.

### Glycopeptide resistance detection (GRD) E-test {#sec008}

GRD E-test (bioMérieux, [Marcy-l\'Étoile, France](https://www.google.com/search?newwindow=1&q=Marcy-l'%C3%89toile&stick=H4sIAAAAAAAAAOPgE-LUz9U3SLMoK6pQ4gIxjQtzzM2NtbSyk63084vSE_MyqxJLMvPzUDhWGamJKYWliUUlqUXFAIlpjw9FAAAA&sa=X&ved=2ahUKEwjwgNLqta_fAhVDcCsKHfAlCqEQmxMoATATegQIBxAL)) was performed, according to the manufacturer instructions. This E-test strip contains a double-sided pre-defined gradient of vancomycin (0.5--32 μg/ml) and teicoplanin (0.5--32 μg/ml). A suspension of bacterial colonies from an overnight culture on blood agar was prepared in MHB, and the turbidity was adjusted to the McFarland standard of 0.5. The inoculum was swabbed onto a Mueller-Hinton agar (MHA) plate containing 5% blood and incubated at 37 ± 2⁰C for 24--48 hrs. The plates were examined at 24 hrs and 48 hrs. The test isolate was considered positive for hVISA, if the MIC of vancomycin or teicoplanin was ≥ 8 μg/ml.

All GRD positive MRSA isolates were screened for heterogeneous resistance to teicoplanin. A 10 μl of 0.5 Mc Farland adjusted bacterial inoculum was plated on to the BHIA plates containing teicoplanin (4--16 μg/ml) and incubated for 48 hrs. The MIC for vancomycin and teicoplanin was retested for colonies which grew on the plates containing 4--16 μg/ml of teicoplanin.

### Population analysis profile-area under curve (PAP-AUC) analysis {#sec009}

Modified PAP-AUC analysis was performed as described by Wootton *et al*. \[[@pone.0227009.ref035]\]. The bacterial strains were incubated in tryptic soy broth (TSB) at 37⁰C for 18--24 hrs. After incubation, the inoculum was diluted 1 in 1000 in saline, 10^−3^ to 10^−6^. The bacterial suspension was plated onto freshly prepared BHIA plates containing 0.5 to 8 μg/ml of vancomycin. Colonies were counted after 48 hrs incubation at 35°C ± 2. For calculation of AUC, viable counts were plotted against increasing concentration of vancomycin using the GraphPad Prism^TM^ (V.7.0) software package. All the PAP-AUC experiments were performed in duplicate. For the vancomycin PAP analysis, the AUC ratio was calculated by dividing the AUC of the test strain by the AUC of the reference MU3 (hVISA) strain. The PAP-AUC ratio was interpreted as follows, \<0.9 as vancomycin-susceptible *S*. *aureus* (VSSA), ≥ 0.9 as hVISA phenotype, \>1.3 as vancomycin-intermediate *S*. *aureus* (VISA). For all the PAP-AUC experiments, the hVISA (MU3, ATCC 700698), VISA (MU50, ATCC 700699), and *S*. *aureus* ATCC 29213 (VSSA) were used as the reference, comparator, and negative control strains, respectively.

Autolysis assay {#sec010}
---------------

Lysis of MRSA strains to Triton X-100 has been used to evaluate the autolytic activity as described by Rodriguez *et al*. \[[@pone.0227009.ref036]\]. Cells were grown to a log-phase to an OD~600~ of about 0.3. The cultures were then rapidly chilled and centrifuged at 14,000 rpm for 10 minutes at 4⁰C. The cell pellet was washed twice with ice-cold water and resuspended in 50 mM Tris/HCl (pH 7.5) containing 0.1% Triton X-100, to achieve an OD~600~ of 1.0. This suspension was incubated at 37⁰C for 4 hrs, and the absorbance was measured every 30 minutes using spectrophotometry. The normalisation of the results was carried out to OD600 at time zero (OD0) using the following formula; percent lysis at a time (t) = (OD~0~-OD~t~)/ OD~0~ X 100. For all experiments, hVISA (MU3, ATCC 700698), VISA (MU50, ATCC 700699), and *S*. *aureus* ATCC 29213 (VSSA) were used as the control strains. Assay results obtained by three independent experiments were expressed as mean ± standard deviation (SD).

Doubling time {#sec011}
-------------

The growth rate of TR-MRSA and hVISA were measured as described by Chen *et al*. \[[@pone.0227009.ref037]\]. For every 30 minutes, a change in OD was monitored for 8hrs. Doubling time of the strain was calculated using the formula; (t~2~-t~1~ x log~2~)/(log OD~600~ at t~2~- log OD~600~ at t~1~); t1 (first sampling time); t2 (second sampling time). hVISA (MU3, ATCC 700698), VISA (MU50, ATCC 700699), and *S*. *aureus* ATCC 29213 (VSSA) were used as control strains. Doubling time of the strains were obtained by three independent experiments and were expressed as mean ± SD.

Extraction of nucleic acids {#sec012}
---------------------------

### Genomic DNA extraction {#sec013}

For DNA extraction, 5--10 morphologically similar colonies from overnight blood agar plates were removed and suspended in 200μl of 1X TE containing 40mg/ml of lysozyme which was incubated at 37⁰C for an hour. The genomic DNA was extracted using the QIAamp DNA Mini Kit according to the manufacturer's instruction. The extracted DNA was eluted in a total volume of 100 μl and stored at -70⁰C.

Accessory gene regulator (*agr*) typing {#sec014}
---------------------------------------

Multiplex PCR was performed for the detection of *agr* types as described by Goudarzi *et al* \[[@pone.0227009.ref038]\].

Staphylococcal cassette chromosome (SCC)*mec* typing {#sec015}
----------------------------------------------------

SCC *mec* typing was performed for all the isolates using multiplex PCR assay \[[@pone.0227009.ref039]\]. SCC *mec* IV subtypes were identified by performing a multiplex PCR assay \[[@pone.0227009.ref040]\]. Control strains of SCC*mec* types I, II, III, IV and V were procured from the Biodefense and Emerging Infections (BEI) Research Resources Repository.

*S*. *aureus* protein A (*spa*) typing {#sec016}
--------------------------------------

For all the hVISA isolates, *spa* typing was performed as described by Harmsen *et al*. \[[@pone.0227009.ref041]\]. Amplified hypervariable region of the *spa* gene was sequenced by using applied biosystem ABI 3130 genetic analyzer. Analysis of nucleotide sequences and the assignment of *spa* type was determined using the *spa* type database Ridom SpaServer ([www.spaserver.ridom.de](http://www.spaserver.ridom.de/)).

Multi-locus sequence typing (MLST) {#sec017}
----------------------------------

MLST was performed on all TR-MRSA and hVISA isolates as described by Enright *et al*. \[[@pone.0227009.ref042]\]. The allelic profile and sequence type (ST) were defined using the MLST database (<https://pubmlst.org/>). MLST clonal complexes were identified using PHYLOViZ, which is restricted to the single locus variant (SLV) and the double locus variant (DLV) of the primary founder in each group \[[@pone.0227009.ref043]\]. MRSA lineages were indicated using the nomenclature MLST-SCC *mec* type.

Genome sequencing, assembly, and annotation {#sec018}
-------------------------------------------

Whole-genome sequencing analysis was performed on all TR-MRSA (*n* = 6) and randomly selected hVISA (*n* = 23) isolates using the Ion Torrent PGM platform. DNA sample concentrations were determined using the Qubit system (Invitrogen). Ion Xpress Plus fragment library kit (Thermo Fisher Scientific, Waltham, MA, USA) was used for the fragmentation of 200--500 ng of genomic DNA, to prepare 400-bp reads according to the manufacturer's instruction. DNA libraries were purified using AMPure XP beads (Beckman Coulter, California, USA). The libraries were then enriched with Ion PGM Hi-Q OT2 kit (Life Technologies, Inc.). Subsequently, genome sequencing was performed using the Ion Torrent Personal Genome Machine platform (Life Technologies, Inc.). The sequencing reads were *de novo* assembled using Assembler SPAdes v5.0.0.0 inbuilt in Torrent suite server version 5.0.3.

*De novo* assembled sequence was further annotated by submitting the sequence to PATRIC, the bacterial bioinformatics database and analysis resource \[[@pone.0227009.ref044]\] and Rapid Annotation using Subsystem Technology (RAST) pipeline \[[@pone.0227009.ref045]--[@pone.0227009.ref047]\] and National Center for Biotechnology Information (NCBI) Prokaryotic Genome Automatic Annotation Pipeline (PGAP).

Mutation analysis {#sec019}
-----------------

Candidate genes in TR-MRSA and hVISA genomes were analysed for amino acid substitutions. These candidate genes include teicoplanin resistant operon (*tca*RAB), *vra*SR, *vra*T, *gra*SR, *wal*KR, and *lyt*SR (regulates the electrical potential of cell membrane); virulence regulating genes *clp*P (stress tolerance and virulence regulation), *pho*R and *sae*S (virulence regulator), *mprF* (multiple peptide resistance factor) and a *msrR* (methionine sulfoxide reductase) gene which is involved in the production of wall-teichoic acid (WTA). In addition, all the genomes were screened for the mutations in penicillin-binding protein (PBP) encoding genes (*pbp*2, *pbp4*) and a *rpo*B gene encoding for β subunit of bacterial RNA polymerase. Hereinafter, all amino acid substitutions are referred as mutations.

These candidate genes were analysed for mutations using ST/clonal complex(CC)- specific VSSA reference genome, DAR4145 (ST772, accession no. CP010526); GR1 (ST672, accession no. AJLX00000000); HO50960412 (ST22, accession no. HE681097); TW20 (ST239, accession no. FN433596); USA400-0051 (ST1, accession no. CP019574); CN1 (ST72, accession no. CP003979); MRSA252 (ST30, accession no. BX571856); N315 (ST5, accession no. BA000018); MCRF184 (ST45, accession no. CP014791).

TW20 was used as the reference genome for mutation analysis of ST368 (SLV of ST239); HO50960412 as a reference genome for ST2371 (SLV of ST22); MRSA252 (as a reference genome for ST1482 (SLV of ST30); N315 as a reference for ST6 (DLV of ST5); MCRF184 as a reference sequence for ST1290 (SLV of ST45).

SIFT (sorting intolerant from tolerant) {#sec020}
---------------------------------------

SIFT (<https://sift.bii.a-star.edu.sg/www/SIFT_seq_submit2.html>) is a sequence-based homology approach which predicts the effect of amino acid substitution on protein function. This algorithm is based on PSI-BLAST \[[@pone.0227009.ref048]\]. SIFT calculates the probabilities for all possible twenty amino acids at each position of the query sequences \[[@pone.0227009.ref049]\]. These probabilities are verified in a scaled probability matrix. Based on this, SIFT calculates the SIFT score or tolerable index (TI) score for every position in the submitted sequences. The SIFT score ranges from 0 to 1. The amino acid substitution is considered to be deleterious, if the score is ≤ 0.05 and tolerated, if the score is \> 0.05.

Protein-Protein Interaction analysis {#sec021}
------------------------------------

The protein-protein interaction analysis was carried out using Cytoscape 3.0 \[[@pone.0227009.ref050]\]. The basic plot of the interaction map was obtained from the STRING database \[[@pone.0227009.ref051]\]. The protein name was given as the input, and *S*. *aureus* was selected as the strain, and the (.tsv) file of the interaction was uploaded to the Cytoscape analysis.

Quantitative real-time reverse transcription PCR (qRT-PCR) {#sec022}
----------------------------------------------------------

The Quantitative reverse transcriptase PCR (RT-PCR) was used to determine the mRNA levels. Expression of PBP2 and PBP4 were studied using the primers and probes as described earlier \[[@pone.0227009.ref052]\]. Complementary DNA (cDNA) was synthesised using 1 μg of total RNA using the QuantiTect Reverse Transcription Kit (Qiagen, France). Quantitative real-time PCR was carried out using ABI fast real-time PCR system and quantiTect Probe PCR Master Mix (Qiagen, France). The concentration of each primer (1 μM) and probe (0.5μM) were used for this qRT-PCR. The difference in expressions was analysed by relative quantification with comparative ΔΔCT method using vancomycin susceptible *S*. *aureus* ATCC 29213 as the comparator \[[@pone.0227009.ref053]\]. Each reaction mixture contains 2μl cDNA in a reaction volume of 20μl with a final concentration of 50 ng. Transcription of PBP was considered upregulated or downregulated when mRNA was expressed at a level of 4-fold higher or lower than that of *S*. *aureus* ATCC 29213. 16s rRNA was used as an internal control. *S*. *aureus* ATCC 700698(MU3, hVISA) and *S*. *aureus* ATCC 700699 (MU50, VISA) were used as the comparator control. Based on their 16s rRNA, all mRNA levels were normalised \[[@pone.0227009.ref054]\]. Normalised *pbp*2 and *pbp*4 fold changes were converted to logarithmic values. All qRT-PCR experiments were performed independently three times.

According to the threshold cycle (CT) values, gene expression was compared and converted to fold change using ΔΔCT. The change in the transcript level was calculated using the formula,

Normalisation to endogenous control: Ct target gene---Ct endogenous control = ΔCt

Normalisation to the reference sample: ΔCt sample - ΔCt reference = ΔΔCt

Use the formula: Fold change = 2^-ΔΔCt^

Ethical clearance {#sec023}
-----------------

The study was approved by the Institutional Review Board of Christian Medical College, Vellore (IRB Min. no 8692 dated 26.02.2014). All the data or samples were fully anonymised before accessing them for further processing. This study only utilised isolates from positive blood cultures, so it doesn't require informed written consent from the patient.

Statistical analysis {#sec024}
--------------------

All statistical analysis was performed using SPSS statistical software (V21.0; SPSS, Inc., Chicago, IL). Sensitivity and specificity were evaluated for BHIV3, BHIV4, MET, and GRD E-test using PAP-AUC as the reference method. Sensitivity and specificity denoted the fraction of true positives and true negatives identified by each method, respectively. Association between the categorical variables were determined using the chi-square (χ^2^) test or Fisher's exact test. Two-tailed student t-test was used to evaluate the statistical significance of data that were expressed as mean ± standard deviation. Transcription changes of PBP2 and PBP4 in mean logarithmic values were compared by one-way analysis of variance (ANOVA) with multiple comparison using Bonferroni corrections. A p-value of \< 0.05 was considered statistically significant.

Results {#sec025}
=======

All tested MRSA isolates demonstrated vancomycin MIC of ≤ 2 μg/ml. Of these, only six had teicoplanin MIC of \> 2 μg/ml. The distribution of vancomycin and teicoplanin MIC is shown in [S1 Fig](#pone.0227009.s001){ref-type="supplementary-material"}. The MIC~50/90~ of vancomycin and teicoplanin were 0.5/1 and 1/2 μg/ml, respectively.

Characterisation of hVISA and TR-MRSA {#sec026}
-------------------------------------

All MRSA isolates (n = 482), were screened for the presence of hVISA subpopulation. Of these, 54% (n = 260), and 26% (n = 127) showed growth on BHIV3 and BHIV4, respectively. In MET, 18% (n = 86) of isolates were found to be positive, and 16% (n = 78) of isolates were considered positive in GRD E-test. Using the vancomycin PAP-AUC method, 13% (n = 64) of the isolates were confirmed as hVISA. The proportion of PAP-AUC confirmed hVISA strains distributed among vancomycin MIC is shown in [Fig 2](#pone.0227009.g002){ref-type="fig"}. Compared to an MIC of 0.5 μg/ml, a higher proportion of hVISA was identified among MRSA strains which had a vancomycin MIC of 1 μg/ml (28% vs. 9%, p \< 0.05). The sensitivity and specificity of the screening methods were as follows, BHIV3 (100% and 53%); BHIV4 (100% and 84%); macro E-test (100% and 94%); and GRD E-test (100% and 96%).

![Distribution of hVISA subpopulation among vancomycin MIC of MRSA isolates recovered from bloodstream infection.](pone.0227009.g002){#pone.0227009.g002}

All GRD positive MRSA isolates were screened for heterogeneous resistance to teicoplanin. Only, six isolates which had a teicoplanin MIC of \> 2 μg/ml ([S1 Fig](#pone.0227009.s001){ref-type="supplementary-material"}) showed growth on the teicoplanin screening agar. Retesting of these isolates showed a one-fold increase in vancomycin MIC (1 to 3 μg/ml) and a two-fold increase in teicoplanin MIC (8 to16 μg/ml for VB9352 and VB23686; 16 to 32 μg/ml for VB31683) ([Table 1](#pone.0227009.t001){ref-type="table"}). Based on the teicoplanin susceptibility, these hVISA strains were classified as, i) TR-MRSA (n = 6) with teicoplanin MIC of 4--32 μg/ml; and ii) hVISA strains (n = 58), with teicoplanin MIC of 1 to 2 μg/ml. The PAP-AUC ratio of these hVISA strains is shown in [S1 Table](#pone.0227009.s002){ref-type="supplementary-material"}.

10.1371/journal.pone.0227009.t001

###### Phenotypic and molecular characterisation of teicoplanin resistant Methicillin resistant *S*. *aureus* (TR-MRSA).

![](pone.0227009.t001){#pone.0227009.t001g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Strain ID   MIC (μg/ml)   Rif   PAP-AUC ratio   ST/SCC*mec* type   *agr* types   Mutations observed in the candidate genes or two-component system (TCS)                                                                                
  ----------- ------------- ----- --------------- ------------------ ------------- ------------------------------------------------------------------------- ----------- --------- ------- ------- ------- ------------------------------ ------------
  VB9352      3             16\   R               0.98 (hVISA)       ST772-V       I                                                                         **D230E**   **Y6R**   T224I   \-      H481Y   **P315R A318Q A319L I320S**\   \-
                                                                                                                                                                                                           **V321M**                      

  VB23686     3             16    S               1.04 (hVISA)       ST772-V       I                                                                         **D230E**   **Y6R**   T224I   \-      \-      \-                             \-

  VB26276     2             4     S               0.98 (hVISA)       ST772-V       II                                                                        **D230E**   **Y6R**   T224I   \-      \-      \-                             \-

  VB12268     3             4     S               1.02 (hVISA)       ST672-IVa     II                                                                        Y237H       H6Y       \-      \-      \-      \-                             \-

  VB169       1.5           4     S               0.97 (hVISA)       ST672-V       II                                                                        Y237H       H6Y       \-      \-      \-      \-                             \-

  VB31683     3             32    S               0.92 (hVISA)       ST22-IVc      I                                                                         **F290S**   \-        \-      D148Q   \-      \-                             **V186I**\
                                                                                                                                                                                                                                          **L144I**\
                                                                                                                                                                                                                                          **V535M**
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Novel mutations are in bold face; previously reported mutations are in unbold text; Van--Vancomycin; Tp--Teicoplanin; Rif--Rifampicin; PAP--population analysis profile; ST--Sequence type; SCC--staphylococcal cassette chromosome.

Genomic characterisation of TR-MRSA and hVISA {#sec027}
---------------------------------------------

### Mutation analysis in TR-MRSA {#sec028}

All six TR-MRSA isolates were negative for both *van*A and *van*B genes. Whole-genome sequence analysis revealed several distinct mutations shown in [Table 1](#pone.0227009.t001){ref-type="table"} and no change in the sequences was seen in *tca*R, *vra*S/R, *vra*T, *wal*K/R, *lyt*R, *clp*P, *sae*S, *msr*R and *mpr*F genes. Novel mutations were identified in *tca*A (D230E, F290S) and *tca*B (Y6R). One isolate (VB9352) had H481Y substitution in *rpo*B gene, which resulted in a rifampicin MIC of \> 32 μg/ml. An amino acid substitution, Y6R in the *tca*B gene, was found to be deleterious with a SIFT score of 0.001. In *lyt*S, five distinct deleterious novel substitutions were identified with the following SIFT scores; P315R (0.01), A318Q (0.001), A319L (0.001), I320S (0.001), and V321M (0.03). Similarly, a novel substitution, V535M (0.03) identified in the *pho*R gene was found to be deleterious. However, a significant association was not seen between high teicoplanin MIC and the accumulation of these mutations.

According to the identified mutations in *tca*AB, *gra*SR, *rpo*B, *lyt*S, and *pho*R genes, four different patterns were found ([Table 1](#pone.0227009.t001){ref-type="table"}). TR-MRSA belonged to three different sequence types (STs), ST772, ST672 and ST22. Among these STs, mutations were frequently observed in *tca*A and *tca*B followed by *gra*S. In VB31683 (ST22), a combination of mutations in *tca*A (F290S), *gra*R (D148Q) and *pho*R (V186I, L144I, V535M) may have resulted in a teicoplanin MIC of 32 μg/ml.

### Genotype and mutation analysis in hVISA {#sec029}

**hVISA genotype.** The genotype of hVISA was determined using SCC*mec* typing, *spa* typing, and MLST ([Fig 3](#pone.0227009.g003){ref-type="fig"}). Seven distinct clonal complexes (CC1, CC5, CC8, CC22, CC30, CC72, CC672) and two singletons (ST616, ST580) were identified. The most representative were CC1 (25%), CC22 (28%) and CC8 (23%). A further sixteen different STs (ST1, ST6, ST22, ST30, ST72, ST239, ST361, ST368, ST382, ST580, ST616, ST672, ST772, ST1290, ST2371, and ST3976) were identified ([Fig 3](#pone.0227009.g003){ref-type="fig"}). The most predominant were ST772 (23%) and ST22 (23%) followed by ST239 (19%). The most common SCC*mec* type was V (35%) followed by SCC*mec* IV (26%) and III (18%). However, *spa* types were highly diverse among these hVISA isolates. The majority of hVISA strains were detected with *agr* I (57%) followed by *agr* II (26%) and *agr* III (17%).

![A phylogenetic tree was constructed based on the seven housekeeping MLST genes of *S*. *aureus* using MEGA V.7.0.\
hVISA strains belonged to different clonal complexes, sequence types and *agr* types were colour coded.](pone.0227009.g003){#pone.0227009.g003}

### Mutations identified in hVISA {#sec030}

Whole-genome analysis of hVISA (n = 23) revealed distinct amino acid substitutions in eleven candidate genes ([Table 2](#pone.0227009.t002){ref-type="table"}). However, none of the tested isolates showed mutations in *tca*R, *vra*T, *wal*K/R, *lyt*S, *clp*P or *msr*R genes. Several novel mutations were identified in *tca*A (D230E, F290S), *tca*B (L173M), *vra*R (T24K), *gra*S (T224K), *rpo*B (N474S, L466S, S486L), *lyt*R (G122D, T118N, N125S), *sae*S (I340M, L203V), *pho*R (V535M) and *mpr*F (T635I, E709D). Of these, the substitutions N474S in *rpo*B and V535M in *pho*R were found to be deleterious with a SIFT score of 0.001.

10.1371/journal.pone.0227009.t002

###### PAP-AUC analysis and amino acid substitutions observed in the candidate genes of hVISA isolated from bloodstream infection.

![](pone.0227009.t002){#pone.0227009.t002g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Strain ID   Van MIC (μg/ml)/ PAP-AUC ratio   Rif   Mutations observed in the candidate genes or two-component system (TCS)                                                                                                                      
  ----------- -------------------------------- ----- ------------------------------------------------------------------------- ----------- ----------- ---------- ----------------- ------------ ----------- ------------ ----------- ----------- ------------
  VB9939      1/0.91 (hVISA)                   S     **D230E**\                                                                \-          \-          \-         T224I             \-           \-          \-           \-          \-          \-
                                                     Y237H                                                                                                                                                                                        

  VB16578     1/0.96 (hVISA)                   S     **D230E**                                                                 \-          \-          \-         T224I             \-           \-          \-           \-          **V535M**   \-

  VB46389     1/1.03 (hVISA)                   S     **D230E**                                                                 \-          \-          **T24K**   T224I             D148Q        \-          \-           \-          **V535M**   \-

  VB7336      1/0.99 (hVISA)                   S     **D230E**                                                                 \-          \-          **T24K**   \-                D148Q        \-          \-           \-          **V535M**   \-

  VB13872     1/0.95 (hVISA)                   S     **D230E**                                                                 \-          \-          \-         \-                D148Q        \-          \-           \-          **V535M**   \-

  VB14468     1/0.97 (hVISA)                   S     **D230E**                                                                 \-          \-          \-         \-                \-           \-          \-           \-          **V535M**   \-

  VB14915     1/1.03 (hVISA)                   S     **D230E**                                                                 \-          \-          \-         \-                \-           \-          \-           \-          **V535M**   \-

  VB103       1/1.0 (hVISA)                    S     **D230E**                                                                 \-          **-**       \-         T224I             D148Q        \-          \-           \-          \-          \-

  VB1919      1/0.92 (hVISA)                   S     **F290S**                                                                 \-          \-          \-         \-                D148Q        \-          \-           \-          \-          \-

  VB44094     1.5/1.23 (hVISA)                 S     **F290S**                                                                 \-          \-          \-         \-                D148Q        \-          \-           \-          **V535M**   **T635I**\
                                                                                                                                                                                                                                                  **E709D**

  VB25679     2/1.27 (hVISA)                   S     **F290S**                                                                 \-          \-          \-         \-                D148Q        \-          \-           **I340M**   \-          \-

  VB9882      1.5/1.03 (hVISA)                 R     **F290S**                                                                 \-          \-          \-         \-                D148Q        **N474S**   \-           **I340M**   **V535M**   **T635I**

  VB20017     1.5/0.96 (hVISA)                 S     **F290S**                                                                 *-*         *-*         \-         T224I             D148Q        \-          \-           **I340M**   \-          **T635I**

  VB1490      1/1.01 (hVISA)                   S     *-*                                                                       *-*         *-*         \-         L26F\             D148Q        \-          **G122D**    \-          \-          \-
                                                                                                                                                                  I59L\                                                                           
                                                                                                                                                                  T224I                                                                           

  VB9190      1/1.1 (hVISA)                    R     *-*                                                                       *-*         V15G        \-         L26F I59L\        D148Q        H481N\      **G122D**    **L203V**   \-          \-
                                                                                                                                                                  R232K                          L466S                                            

  VB14511     1/0.92 (hVISA)                   S     *-*                                                                       *-*         V15G        \-         L26F, I59L        D148Q        \-          **G122D**    **L203V**   \-          \-

  VB43011     1/1.28 (hVISA)                   R     *-*                                                                       *-*         *-*         \-         T224I\            \-           **S486L**   \-           \-          \-          \-

  VB44746     1/1.26 (hVISA)                   S     *-*                                                                       *-*         *-*         \-         L26F\             \-           \-          \-           \-          \-          \-
                                                                                                                                                                  T224I                                                                           

  VB4283      1/1.25 (hVISA)                   S     *-*                                                                       **L173M**   *-*         \-         T224I\            D148Q        \-          \-           \-          \-          \-

  VB7185      1/0.9 (hVISA)                    S     *-*                                                                       *-*         *-*         \-         L26F\             D148Q        \-          \-           **L203V**   \-          \-
                                                                                                                                                                  I59L\                                                                           
                                                                                                                                                                  T224I                                                                           

  VB43964     1/1.02 (hVISA)                   S     *-*                                                                       *-*         *-*         \-         T224I             **D147E**\   \-          \-           \-          \-          \-
                                                                                                                                                                                    D148Q                                                         

  VB3985      1/1.14 (hVISA)                   S     L218P\                                                                    K396R       **H6Y**\    \-         L26F, **T224K**   \-           \-          **T118N**\   \-          \-          \-
                                                     G312D                                                                                 **K396R**                                                         **N125S**                            

  VB35316     1/0.96 (hVISA)                   S     *-*                                                                       *-*         *-*         \-         T224I             \-           \-          **E31D**     \-          \-          \-
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Novel mutations are in bold face; previously reported mutations are in unbold text; Van--Vancomycin Rif--Rifampicin; PAP--population analysis profile

Based on the identified mutations in hVISA, 26 different patterns were identified ([S2 Table](#pone.0227009.s003){ref-type="supplementary-material"}). Among hVISA, D148Q (65%) in *gra*R was identified as the predominant mutation followed by T224I (52%) substitution in *gra*S, and D230E (35%) in *tca*A. A strong link was seen between hVISA phenotype and the mutations identified in *tca*A (D230E), *gra*S (T224I) and *gra*R (D148Q) (p \<0.05). Of these mutations, T224I and D148Q were identified in various STs ([S2 Table](#pone.0227009.s003){ref-type="supplementary-material"}) and D230E substitution was most commonly seen among the hVISA strains which belonged to ST772.

### Difference in the mutation between TR-MRSA and hVISA {#sec031}

A large number of mutations were identified in the candidate genes of TR-MRSA and hVISA (Tables [1](#pone.0227009.t001){ref-type="table"} and [2](#pone.0227009.t002){ref-type="table"}). Many non-overlapping mutations were identified in both TR-MRSA and hVISA ([S3 Table](#pone.0227009.s004){ref-type="supplementary-material"}). However, mutations in *tca*A (D230E, Y237H, F260S), *gra*S (T224I) and *gra*R (D148Q) were shared by both TR-MRSA and hVISA.

Triton X-100 induced autolysis {#sec032}
------------------------------

The autolysis rate of TR-MRSA to triton X-100 is shown in [Fig 4](#pone.0227009.g004){ref-type="fig"}. TR-MRSA strains showed significantly decreased autolytic activity, as compared to *S*. *aureus* ATCC 29213 (p \<0.05) ([S4 Table](#pone.0227009.s005){ref-type="supplementary-material"}). However, only two TR-MRSA strains (VB9352, VB31683) showed decreased autolytic activity compared to MU3 (p \<0.01). The autolysis rate observed in three TR-MRSA strains (VB23686, VB31683, VB9352) were almost comparable to that of the MU50 strain. Triton X-100 induced autolytic rate of hVISA strains are shown in the [S5 Table](#pone.0227009.s006){ref-type="supplementary-material"}. Although hVISA strains showed decreased autolytic rates, this was not significant as compared to *S*. *aureus* ATCC 29213.

![Triton X-100 induced autolysis in teicoplanin resistant MRSA (TR-MRSA).\
Lysis of cells was measured as the percentage of absorbance measured at OD600nm. The data are represented as mean ± mean standard deviation (SD). a) Triton X-100 induced autolysis in TR-MRSA with MICs of 16 and 32 μg/ml; b) Triton X-100 induced autolysis in TR-MRSA with MIC of 4 μg/ml. The autolysis rate of all TR-MRSA strains was significantly higher than *S*. *aureus* ATCC 29213 (p \<0.05). VB9352 and VB31683 showed decreased lytic activity than MU3 (p \<0.01).](pone.0227009.g004){#pone.0227009.g004}

Doubling time {#sec033}
-------------

The doubling times of TR-MRSA, ranged from 33.7 to 37.7 minutes. TR-MRSA strains (VB23686, VB31683, VB9352) had a significantly longer doubling times (p \< 0.05) than *S*. *aureus* ATCC 29213 ([S4 Table](#pone.0227009.s005){ref-type="supplementary-material"}). The doubling time of these strains was almost comparable to MU3 but was shorter than for the MU50 strain. Among hVISA, the doubling time ranged from 32.4 to 36.8 minutes. Nineteen hVISA strains had a significantly longer doubling time than *S*. *aureus* ATCC 29213 (p \< 0.05) ([S5 Table](#pone.0227009.s006){ref-type="supplementary-material"}). All these hVISA strains had a doubling time, comparable to that of the MU3 strain.

Protein network analysis of TCS involved in cell wall biosynthesis {#sec034}
------------------------------------------------------------------

The protein-protein interaction analysis predicted that *tca*A showed co-expression with *tca*R, *pbp*2, *vra*R, *vra*S, *msr*R and *mur*A2. Similarly, *wal*K showed co-expression with *gra*R, *gra*S, *wal*K, *vra*R and *sae*S. A functional change induced by the mutations in the *tca*RAB, vraSR, *gra*SR, or *wal*KR TCS, can alter the functioning of other interacting proteins. The *vra*SR TCS was predicted to be directly associated with *pbp*2 ([Fig 5](#pone.0227009.g005){ref-type="fig"}). Amino acid substitution induced changes in *vra*SR may influence the expression of *pbp*2.

![Protein network analysis of selected cell wall biosynthesis regulating genes.\
a) protein-protein interaction analysis of *tca*A and *tca*B; b) protein-protein interaction analysis of *vra*R, *vra*S, *gra*S, and *gra*R.](pone.0227009.g005){#pone.0227009.g005}

Quantitative transcript analysis of *pbp2* and *pbp4* {#sec035}
-----------------------------------------------------

Transcriptional changes in *pbp*2 and *pbp*4 were evaluated in both TR-MRSA (n = 6) and hVISA (n = 23) using qRT-PCR. In addition, genomes of TR-MRSA and hVISA were analysed for amino acid substitutions. Eleven distinct substitutions (P285A, T439V, A420V, A557T, T691A, P825A, T489E, H121R, R262C, A172T) in *pbp*2 and seven different substitution (D98E, T253P, E398A, T25A, Q283A, S395C, A409T) in *pbp*4 were observed ([S6 Table](#pone.0227009.s007){ref-type="supplementary-material"}). In TR-MRSA, *pbp*2 upregulation was found to be significant in VB9352 (2.5-fold), VB23686 (2.2-fold), and VB31683 (3.1-fold), compared to *S*. *aureus* ATCC 29213 (p \< 0.01) ([Fig 6](#pone.0227009.g006){ref-type="fig"}). Similarly, downregulation of *pbp*4 in VB9352 (0.2-fold), VB23686 (0.2-fold), and VB31683 (2.4-fold) were significant, compared to *S*. *aureus* ATCC 29213 (p \< 0.01) ([Fig 6](#pone.0227009.g006){ref-type="fig"}). One isolate VB31683 had significant *pbp*4 downregulation compared to the MU3 strain (p \< 0.01). Compared to *S*. *aureus* ATCC 29213, *pbp*2 upregulation was found to be significant in four hVISA strains which include VB9882 (2.1-fold), VB20017(1.9-fold), VB44094 (2.1-fold), and VB25679 (1.9-fold) (p \< 0.05) ([Fig 7](#pone.0227009.g007){ref-type="fig"}). Significant *pbp4* downregulation was observed in only one hVISA (VB25679, 0.3-fold) strain (p \<0.01).

![Quantitative transcription of *pbp*2 and *pbp*4 genes among TR-MRSA strains (n = 6).\
Data are indicated as mean and standard deviation. Error bar represents the standard deviation of three mean values. Upregulation of *pbp*2 and downregulation of *pbp*4 were significant in VB9352, VB23686, and VB31683 compared to *S*. *aureus* ATCC 29213 (marked with a single asterisk, p \< 0.01). VB31683 showed significant *pbp*4 downregulation compared to the MU3 strain (marked with a double asterisk, p \< 0.01). Expression levels of *pbp*2 were comparable to that of the MU3 strain.](pone.0227009.g006){#pone.0227009.g006}

![Quantitative transcription of *pbp*2 and *pbp*4 genes in whole-genome sequenced hVISA strains (n = 23).\
Data are indicated as mean and standard deviation. Error bar represents the standard deviation of three mean values. *pbp*2 upregulation was significant in VB9882, VB20017, VB44094, and VB25679 compared to *S*. *aureus* ATCC 29213 (marked with a single asterisk, p \< 0.05). *pbp*4 upregulation was significant in VB25679 compared to *S*. *aureus* ATCC 29213 (marked with a single asterisk, p \< 0.05).](pone.0227009.g007){#pone.0227009.g007}

Compared to MU3, *pbp*2 upregulation and *pbp*4 downregulation were significant in the TR-MRSA strain VB31683 (p \< 0.01). However, none of the tested TR-MRSA strains had significant changes in the transcription of *pbp*2 and *pbp*4, compared to MU50. Similarly, in all the tested hVISA strains, fold changes in *pbp*2 and *pbp*4 transcription were not significant, compared to MU3.

Accession numbers {#sec036}
-----------------

All draft genomes used in this study were deposited under DDBJ/ENA/GenBank under the accession numbers as provided in the [S7 Table](#pone.0227009.s008){ref-type="supplementary-material"}.

Discussion {#sec037}
==========

In recent years, hVISA and VISA associated vancomycin treatment failure are becoming an increasing clinical challenge. Several studies have reported the occurrence of vancomycin MIC creep in *S*. *aureus* \[[@pone.0227009.ref055]--[@pone.0227009.ref057]\]. Vancomycin and teicoplanin exhibit antimicrobial activity by binding to D-Ala-D-Ala subunits of the murein monomer. Therefore, cross-resistance can be expected between these antibiotics. The thickening of the cell wall contributes to the development of vancomycin and teicoplanin non-susceptibility in *S*. *aureus*.

The lack of universal resistance markers in hVISA/VISA strains, is a major problem in understanding the genetic mechanism of glycopeptide resistance. The genes *vra*SR, *gra*SR, *wal*KR and *rpo*B have been frequently associated with the development of heterogeneous resistance to vancomycin \[[@pone.0227009.ref008]\]. The *tca*RAB operon has been reported to contribute to the development of teicoplanin resistance in *S*. *aureus* \[[@pone.0227009.ref058],[@pone.0227009.ref059]\]. Here, we examined the presence of mutations in the TCS operon (*tca*RAB, *vra*SR, *vra*T, *gra*SR, *wal*KR, *lyt*SR) and genes (*rpo*B, *clp*, *sae*S, *pho*R, *pbp*2, *pbp*4) in TR-MRSA and hVISA strains. All these loci have been reported as crucial markers for the development of hVISA/VISA strains \[[@pone.0227009.ref008],[@pone.0227009.ref060]\].

Studies have reported TR-MRSA infection with a teicoplanin and vancomycin MIC of 16 μg/ml and 2 μg/ml, respectively \[[@pone.0227009.ref061],[@pone.0227009.ref062]\]. A meta-analysis showed a pooled prevalence of 6% hVISA and 3% VISA from reports available across the world \[[@pone.0227009.ref011]\]. In India, the prevalence of hVISA ranges from 5.8% to 6.9% \[[@pone.0227009.ref063],[@pone.0227009.ref064]\]. Interestingly, our study documented the presence of 1% TR-MRSA and 12% hVISA amongst MRSA isolates from bloodstream infection. In contrast to previous reports from India, a high prevalence of hVISA was observed in this study.

In this study, we noted novel mutations in important candidate genes *tca*A (D230E, F290S); *tca*B (Y6R, L173M); *vra*S (H6Y, K396R); *vra*R (T24K); *gra*S (T224K); *gra*R (D147E) and *rpo*B (S486L). Mutations in *yvq*F and *vra*SR are reported to be associated with the development of TR-MRSA \[[@pone.0227009.ref021]\]. However, a similar mutation pattern was not noted in our study. In *S*. *aureus*, *tca*A mutants contribute to the development of VISA \[[@pone.0227009.ref065], [@pone.0227009.ref066]\]. We identified novel mutations in *tca*A and *tca*B. Multiple mutations in *vra*SR loci are frequently associated with hVISA/VISA development \[[@pone.0227009.ref067]\]. The presence of V15G mutation in *vra*S is associated with increased vancomycin MIC in VISA phenotypes \[[@pone.0227009.ref068]\]. Notably, in our study, this substitution was identified in hVISA strains. However, a significant rise in vancomycin MIC did not occur in these strains.

Mutation in *gra*S (L26F, I59L, T224I) has not only been reported in hVISA/VISA strains, but also identified in VSSA strains \[[@pone.0227009.ref065],[@pone.0227009.ref066],[@pone.0227009.ref069]\]. In our study, these mutations were noted in both TR-MRSA and hVISA phenotypes, but the significance of these mutations remains unclear. In *gra*R, the D184Q mutation is reported to be strongly associated with the development of hVISA phenotypes \[[@pone.0227009.ref070]\]. Similarly, in this study, 65% of the tested hVISA strains had D184Q as the predominant substitution.

In *rpo*B, H48IY/N is the predominant loci contributing to the development of dual resistance to rifampicin and vancomycin \[[@pone.0227009.ref068],[@pone.0227009.ref071]\]. In our study, all *rpo*B mutations were identified in the rifampicin resistance determining region (RRDR), which spans amino acid residues between positions 463--550. A novel mutation identified in the *rpo*B (S488L) gene of the tested isolate resulted in an increased rifampicin MIC of \>32 μg/ml. A large number of distinct mutations were observed, however none of them reliably differentiated TR-MRSA from hVISA strains.

The heterogeneous clonal background could contribute to the diverse mutations observed in this study. Most of the reported hVISA/VISA strains belong to ST5 (clonal complex, CC5) or ST239 (CC8) \[[@pone.0227009.ref008]\]. Remarkably, in our study, sixteen different STs belonged to eight different CCs. A significant association was not noted between STs and amino acid substitutions. However, mutations in *tca*A (D230E) and *gra*S (T224I) were commonly seen in ST772 MRSA strains, whilst a D148Q mutation in *gra*R was seen in diverse STs. This reflects the adaptation of different MRSA genotypes to develop TR-MRSA/hVISA phenotypes. This is the first study to report TR-MRSA and hVISA strains belonging to ST772 and ST22.

A change in the expression of *pbp*2 and *pbp*4 leads to a thickened cell wall in *S*. *aureus* with reduced vancomycin susceptibility \[[@pone.0227009.ref072]\]. Upregulation of *pbp*2 promotes cell wall synthesis, and downregulation of *pbp*4 results in decreased murein cross-linking \[[@pone.0227009.ref073]\]. These substantial changes may result in increased production of D-Ala-D-Ala subunits which trap most of the vancomycin molecule. In our study, significant *pbp*2 upregulation was noted in TR-MRSA (MIC 16 or 32 μg/ml) and four hVISA strains. However, none of the tested isolates showed significant *pbp*4 downregulation. This could be due to differences in the mutation occurring in co-expressed genes which are involved in cell wall synthesis.

Studies have reported the potential association between *agr* dysfunction and hVISA/VISA \[[@pone.0227009.ref074]\]. Harigaya *et al*. reported *agr* dysfunction in hVISA strains was five times more than that of VSSA strains \[[@pone.0227009.ref075]\]. A study from India reported 82.8% of hVISA isolates carried *agr* group I loci. Similarly, in this study, the majority of tested strains belong to *agr* group I.

A limitation of our study is that the genetic effects of the novel mutation on vancomycin susceptibility were not investigated.

Conclusion {#sec038}
==========

In conclusion, we describe the presence of TR-MRSA and hVISAs isolated from bloodstream infection. A significantly higher proportion of hVISA isolates were identified among MRSA isolates with vancomycin MIC of ≥ 1 μg/ml. A large number of mutations were identified in the candidate genes. This indicates the complex evolutionary pathway involved in the development of TR-MRSA and hVISA. However, none of the markers were reliable in differentiating hVISA from TR-MRSA phenotypes. Considerably significant upregulation of *pbp*2 was noted in the strains with high teicoplanin MICs of 16 or 32 μg/ml. Mutated *tca*RAB, *vra*SR, *gra*SR, and *rpo*B *may* influence the transcription of the cell wall biosynthesis gene.
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